Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Atterocor Announces Data Presentations at ICE/ENDO 2014

Thursday, June 12, 2014   (0 Comments)
Share |
Atterocor, Inc., a company developing a novel therapy for adrenal cancer, today announced that the company’s chief scientific officer, Stephen W. Hunt, III, Ph.D., will present preclinical data on ATR-101 in an oral session at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014), being held June 21-24 at McCormick Place West in Chicago. The company will also present a poster at the XVIth Conference on the Adrenal Cortex (ADRENAL 2014), a satellite meeting being held immediately prior to ICE/ENDO 2014. ATR-101 is the company’s novel, oral drug candidate in a Phase 1 clinical study for the treatment of adrenocortical carcinoma (ACC). ATR-101 is a selective inhibitor of ACAT1, which reduces adrenal steroids and induces apoptosis of cells derived from the adrenal cortex. 

“The in vitro and in vivo data to be presented at ICE/ENDO provide a deeper understanding of the biology of ATR-101 and insight into the unique impact of this compound in adrenal cancer cells,” said Julia C. Owens, Ph.D., president and chief executive officer of Atterocor. “Based on these new data and the selective effects that ATR-101 has shown on adrenal cortex-derived cells in other preclinical studies to date, we believe ATR-101 shows strong potential to have a positive impact in the treatment of ACC, a very rare cancer with particularly poor patient prognosis, as well as other adrenal diseases. We are pleased that these updates on ATR-101 will be featured during the world’s largest endocrinology meeting in one oral and three poster presentations, including one resulting from our collaboration with Dr. Gary Hammer’s lab at the University of Michigan.”
The schedule of ATR-101 presentations at ICE/EDO 2014 and ADRENAL 2014 is as follows: 

ICE/ENDO 2014 Oral Presentation 

Title: ATR-101, a Selective ACAT1 Inhibitor in Development for Adrenocortical Carcinoma, Disrupts Steroidogenesis and Causes Apoptosis in Normal Canine Adrenals 
Session: OR14-Adrenal Tumors: Novel Causes and Mechanisms Translational 
Date/Time: Sunday, June 22, 2014, 12:30 p.m. 
Location: W196 
Presentation: OR14-5 
Presenter: Stephen W. Hunt, III, PhD, chief scientific officer, Atterocor 

ICE/ENDO 2014 Poster Presentations 

ATR-101, a Selective and Potent Inhibitor of ACAT1, Causes Apoptosis 
in H295R ACC Cells 
Session: SAT 0781-0797-Adrenal Tumors: ACC & Adrenal Incidentaloma / 
Date/Time: Saturday, June 21, 2014, 1-3:00 p.m. 
Location: Hall F 
Poster: SAT-0792 
Presenter: Christopher R. Lapensee, PhD, University of Michigan 
Title: ATR-101 Phase 1 Clinical Study for Adrenocortical Carcinoma 
Session: SAT 0798-0817-Adrenal Tumors: ACC & Incidentaloma Clinical/Translational 
Date/Time: Saturday, June 21, 2014, 1-3:00 p.m. 
Location: Hall F 
Poster: SAT-0811 
Presenter: Aung Naing, MD, The University of Texas MD Anderson Cancer Center 

ADRENAL 2014 Poster Presentation
Title: Effects On Steroidogenesis And Apoptosis In Normal Canine Adrenals Caused By ATR-101, A Selective ACAT1 Inhibitor In Development For Adrenocortical Carcinoma 
Date/Time: Wednesday, June 18, 2014, 3-5:30 p.m. 
Location: Lasalle II 
Poster: 46 
Presenter: Stephen W. Hunt, III, PhD, chief scientific officer, Atterocor 
About Adrenal Cancer 
Adrenal cancer is often diagnosed in the late stages of disease when there is a very poor patient prognosis. Adrenocortical carcinoma (ACC) is a cancer of the adrenal cortex that occurs when cancer cells form in the outer layer (cortex) of the adrenal gland. This form of cancer is rare, with approximately 500 to 600 patients diagnosed in the U.S. each year and around 1,000 patients in the U.S. overall. Current treatment options are often toxic, ineffective and poorly tolerated in many patients, and surgery is not a viable treatment option for the majority of ACC patients. With limited treatment options, there exists a desperate need for new therapies for adrenal cancer.
About Atterocor, Inc. 
Atterocor is focused on the development of ATR-101, a novel, oral drug candidate for the treatment of adrenocortical carcinoma (ACC). Founded in 2012, Atterocor is backed by $16 million in Series A venture capital financing from top-tier life sciences investors Frazier Healthcare, Osage University Partners and 5AM Ventures, along with the Regents of the University of Michigan under the MINTS program (Michigan Investment in New Technology Startups) and The Michigan Pre-Seed Capital Fund, an MEDC program managed by Ann Arbor Spark. Atterocor is based in Ann Arbor, Michigan.

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by®  ::  Legal